Age‑Adapted Chemotherapy Plus MRD‑Directed Transplantation Improves Safety Without Sacrificing Efficacy in Ph‑Negative Adult ALL: Key Findings from GRAALL‑2014
Posted inHematology-Oncology news Oncology

Age‑Adapted Chemotherapy Plus MRD‑Directed Transplantation Improves Safety Without Sacrificing Efficacy in Ph‑Negative Adult ALL: Key Findings from GRAALL‑2014

The GRAALL‑2014 trial shows that age‑adapted chemotherapy with MRD‑guided alloHSCT reduces early mortality and transplant use while maintaining disease‑free survival in adults (18–59) with Ph‑negative ALL; 4‑year DFS was 57.1% and overall survival improved across age groups.